Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multidisciplinary approach in the management of hATTR.
Losada I, González-Moreno J, Rodriguez A, Uson M, Ripoll-Vera T, Ferrer-Nadal A, Rigo E, Andreu H, Figuerola A, Montalà JC, Descals C, Álvarez J, Vega-Mañés F, Roig A, Cisneros-Barroso E. Losada I, et al. Eur J Clin Invest. 2020 Oct;50(10):e13296. doi: 10.1111/eci.13296. Epub 2020 Aug 11. Eur J Clin Invest. 2020. PMID: 32474919 No abstract available.
Amyloidotic breast nodule in hereditary transthyretin amyloidosis (hATTR): a case report.
Cisneros-Barroso E, Losada-López I, González-Moreno J, Buades J, Ferrer-Nadal A, Ripoll-Vera T, Usón M, Figuerola A, Montalà JC, Descals C, Salva-Ramonell F, Torres-Rovira J, Gene-Heym A, Fernández-Burgos I, Soler T. Cisneros-Barroso E, et al. Amyloid. 2019;26(sup1):59-60. doi: 10.1080/13506129.2019.1582521. Amyloid. 2019. PMID: 31343326 No abstract available.
Significant reduction in proteinuria after treatment with tafamidis.
Ferrer-Nadal A, Ripoll T, Uson M, Figuerola A, Andreu H, Losada I, Gonzalez J, Cisneros-Barroso E, Buades J. Ferrer-Nadal A, et al. Amyloid. 2019;26(sup1):67-68. doi: 10.1080/13506129.2019.1583186. Amyloid. 2019. PMID: 31343359 No abstract available.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden.
González-Moreno J, Gaya-Barroso A, Losada-López I, Rodríguez A, Bosch-Rovira T, Ripoll-Vera T, Usón M, Figuerola A, Descals C, Montalà C, Ferrer-Nadal MA, Cisneros-Barroso E. González-Moreno J, et al. Among authors: cisneros barroso e. Orphanet J Rare Dis. 2021 Jun 10;16(1):266. doi: 10.1186/s13023-021-01910-5. Orphanet J Rare Dis. 2021. PMID: 34112225 Free PMC article.
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J, Losada-López I, Cisneros-Barroso E, Garcia-Pavia P, González-Costello J, Muñoz-Beamud F, Campistol JM, Fernandez-Torron R, Chapman D, Amass L. González-Moreno J, et al. Among authors: cisneros barroso e. Neurol Ther. 2021 Dec;10(2):833-845. doi: 10.1007/s40120-021-00267-y. Epub 2021 Jul 30. Neurol Ther. 2021. PMID: 34331265 Free PMC article.
Accessibility to Occupational Therapy Services for Hereditary Transthyretin Amyloidosis.
Gayà-Barroso A, González-Moreno J, Rodríguez A, Ripoll-Vera T, Losada-López I, Gili M, Cisneros-Barroso E. Gayà-Barroso A, et al. Among authors: cisneros barroso e. Int J Environ Res Public Health. 2022 Apr 7;19(8):4464. doi: 10.3390/ijerph19084464. Int J Environ Res Public Health. 2022. PMID: 35457333 Free PMC article.
20 results